Revvity (NYSE:RVTY) Releases Earnings Results, Beats Expectations By $0.05 EPS

Revvity (NYSE:RVTY - Get Free Report) posted its quarterly earnings results on Friday. The company reported $1.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.37 by $0.05, RTT News reports. Revvity had a return on equity of 7.68% and a net margin of 9.81%. During the same period last year, the company posted $1.25 EPS. Revvity updated its FY 2025 guidance to 4.900-5.000 EPS.

Revvity Stock Down 0.4 %

NYSE:RVTY traded down $0.53 on Tuesday, hitting $123.16. The stock had a trading volume of 839,046 shares, compared to its average volume of 903,647. The firm's fifty day simple moving average is $117.06 and its two-hundred day simple moving average is $118.90. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.03 and a current ratio of 3.60. The stock has a market cap of $14.99 billion, a P/E ratio of 55.73, a price-to-earnings-growth ratio of 4.17 and a beta of 1.03. Revvity has a 1 year low of $97.32 and a 1 year high of $129.50.

Revvity Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, May 9th. Investors of record on Friday, April 18th will be issued a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.23%. The ex-dividend date is Thursday, April 17th. Revvity's dividend payout ratio is currently 12.67%.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on RVTY. Bank of America raised shares of Revvity from a "neutral" rating to a "buy" rating and set a $138.00 target price for the company in a research report on Friday, December 13th. Raymond James reaffirmed an "outperform" rating and set a $145.00 price objective (up previously from $140.00) on shares of Revvity in a research report on Monday. TD Cowen lifted their price target on shares of Revvity from $141.00 to $144.00 and gave the company a "buy" rating in a report on Tuesday, November 5th. Leerink Partners increased their target price on Revvity from $130.00 to $135.00 and gave the company an "outperform" rating in a research report on Thursday, October 17th. Finally, Barclays raised their price objective on shares of Revvity from $135.00 to $140.00 and gave the company an "overweight" rating in a report on Monday. Four equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Revvity currently has an average rating of "Moderate Buy" and a consensus price target of $136.25.

Insiders Place Their Bets

In related news, insider Tajinder S. Vohra sold 5,492 shares of the company's stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $116.81, for a total transaction of $641,520.52. Following the sale, the insider now directly owns 19,652 shares in the company, valued at approximately $2,295,550.12. This represents a 21.84 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Joel S. Goldberg sold 15,170 shares of the stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $126.73, for a total value of $1,922,494.10. Following the sale, the insider now directly owns 33,400 shares in the company, valued at $4,232,782. This trade represents a 31.23 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.60% of the company's stock.

Revvity announced that its board has approved a stock buyback plan on Monday, November 4th that permits the company to repurchase $1.00 billion in shares. This repurchase authorization permits the company to reacquire up to 6.5% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company's board believes its stock is undervalued.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.